# FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)

> **NCT00398931** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 1099 (actual)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **DRUG:** MK0217, alendronate sodium / Duration of Treatment : 5 Years
- **DRUG:** Comparator : placebo (unspecified) /Duration of Treatment : 5 Years

## Key facts

- **NCT ID:** NCT00398931
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-02
- **Primary completion:** 2003-10
- **Final completion:** 2003-10
- **Target enrollment:** 1099 (ACTUAL)
- **Last updated:** 2022-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00398931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00398931, "FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00398931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*